Molecular Pathology: Genetic Testing Explained

”

Your cancer is as unique as you are. Molecular pathology examines the genetic changes in your cancer cells to guide personalized treatment. According to the American Association for Cancer Research, molecular testing has revolutionized cancer care by matching targeted therapies to specific genetic alterations.

Molecular pathology is a specialized field that analyzes DNA, RNA, and proteins to understand the genetic changes driving cancer. Unlike traditional pathology, which looks at cells under a microscope, molecular pathology examines the molecular blueprint of cancer.

The Genetic Basis of Cancer

Cancer is a genetic disease:

• Caused by changes (mutations) in DNA
• These mutations affect how cells grow and divide
• Different mutations cause different types of cancer
• Understanding mutations helps guide treatment

Types of genetic changes:

• Mutations: Changes in DNA sequence
• Amplifications: Too many copies of a gene
• Deletions: Missing pieces of DNA
• Rearrangements: DNA pieces swapped between chromosomes
• Fusions: Two genes joining together

How Molecular Testing Works

The process:

1. Tissue acquisition: From biopsy, surgery, or blood
2. DNA/RNA extraction: Isolating genetic material
3. Analysis: Using various technologies to find changes
4. Interpretation: Determining what changes mean
5. Report: Providing actionable information to clinicians

Testing technologies:

• Next-generation sequencing (NGS): Tests many genes at once
• PCR: Tests specific known mutations
• FISH: Finds gene rearrangements and amplifications
• IHC: Detects protein expression
• Microarray: Tests gene expression patterns

Breast Cancer Markers

ER (Estrogen Receptor) and PR (Progesterone Receptor):

• What they are: Receptors for hormones
• What they mean: Cancer may respond to hormone therapy
• Testing: Immunohistochemistry (IHC)
• Treatment implication: Hormone-blocking therapies

HER2 (Human Epidermal Growth Factor Receptor 2):

• What it is: Protein that promotes cell growth
• What it means: HER2-positive cancers may respond to targeted therapy
• Testing: IHC first, then FISH if needed
• Treatment implication: HER2-targeted therapies (trastuzumab, etc.)

BRCA1 and BRCA2:

• What they are: Genes that repair DNA damage
• What they mean: Mutations increase cancer risk and affect treatment
• Testing: Germline genetic testing
• Treatment implication: PARP inhibitors, different surgical approaches

Lung Cancer Markers

EGFR (Epidermal Growth Factor Receptor):

• What it is: Gene that helps cells grow
• What it means: Mutations may respond to EGFR inhibitors
• Testing: NGS or PCR
• Treatment implication: EGFR-targeted therapies

ALK (Anaplastic Lymphoma Kinase):

• What it is: Gene rearrangement that drives cancer growth
• What it means: May respond to ALK inhibitors
• Testing: FISH or NGS
• Treatment implication: ALK-targeted therapies

KRAS:

• What it is: Gene involved in cell signaling
• What it means: Mutations affect treatment response
• Testing: NGS or PCR
• Treatment implication: May not respond to EGFR inhibitors, but newer KRAS inhibitors available

PD-L1:

• What it is: Protein that helps cancer evade immune system
• What it means: May predict response to immunotherapy
• Testing: IHC
• Treatment implication: Immune checkpoint inhibitors

Colorectal Cancer Markers

KRAS, NRAS, BRAF:

• What they are: Genes in cell signaling pathways
• What they mean: Mutations affect treatment options
• Testing: NGS or PCR
• Treatment implication: Determines eligibility for EGFR inhibitors

MSI (Microsatellite Instability) and MMR (Mismatch Repair):

• What they are: Indicators of DNA repair deficiency
• What they mean: May respond to immunotherapy
• Testing: IHC or PCR
• Treatment implication: Immune checkpoint inhibitors

NTRK fusions:

• What they are: Rare gene fusions
• What they mean: May respond to NTRK inhibitors
• Testing: NGS
• Treatment implication: Tissue-agnostic NTRK inhibitors

Other Important Markers

MSI-H/dMMR:

• Found in many cancer types
• Indicates defective DNA repair
• Predicts response to immunotherapy
• Tissue-agnostic indication for immunotherapy

NTRK fusions:

• Rare but found in many cancer types
• Highly responsive to NTRK inhibitors
• Tissue-agnostic treatment approach

TMB (Tumor Mutational Burden):

• Measure of total mutations
• High TMB may predict immunotherapy response
• Varies widely between cancer types

Single Gene Testing

What it tests: One specific gene or mutation

When used:

• When a specific mutation is suspected
• For common, well-characterized mutations
• When results are urgently needed

Advantages:

• Faster results
• Lower cost
• Well-established interpretation

Limitations:

• May miss other mutations
• May need additional testing later
• Less comprehensive

Gene Panels

What it tests: Multiple genes at once (10-500+ genes)

When used:

• When multiple mutations are possible
• For comprehensive profiling
• When tissue is limited

Advantages:

• Tests many genes simultaneously
• More efficient than single gene tests
• Can find unexpected mutations
• Uses less tissue

Limitations:

• More expensive than single tests
• May find variants of uncertain significance
• Longer turnaround time

Whole Exome Sequencing

What it tests: All protein-coding genes (~20,000 genes)

When used:

• Research settings
• When standard tests are inconclusive
• For rare or unusual cancers

Advantages:

• Most comprehensive
• May find rare mutations
• Useful for research

Limitations:

• Expensive
• Results complex to interpret
• May find incidental findings
• Not routinely needed

Liquid Biopsy Molecular Testing

What it tests: Circulating tumor DNA in blood

When used:

• When tissue biopsy not possible
• For monitoring treatment response
• For detecting resistance mutations
• When tissue is insufficient

Advantages:

• Non-invasive
• Can be repeated frequently
• Captures tumor heterogeneity

Limitations:

• May not detect all mutations
• Less sensitive than tissue testing
• Not yet standard for all situations

Targeted Therapy

What it is: Drugs that specifically target molecular abnormalities in cancer cells

How it works:

• Identifies specific molecular changes driving cancer growth
• Matches drugs that target those specific changes
• Often more effective and less toxic than chemotherapy

Examples:

• EGFR inhibitors for EGFR-mutant lung cancer
• HER2-targeted therapies for HER2-positive breast cancer
• BRAF inhibitors for BRAF-mutant melanoma
• ALK inhibitors for ALK-rearranged lung cancer
• PARP inhibitors for BRCA-mutated cancers

Immunotherapy

What it is: Treatments that help the immune system fight cancer

Molecular predictors:

• PD-L1 expression: Higher levels may predict better response
• MSI-H/dMMR: Strong predictor of response
• High TMB: Associated with better response
• Specific gene mutations: May predict response or resistance

Why molecular testing matters:

• Identifies patients most likely to benefit
• Spares unlikely responders from unnecessary toxicity
• Guides treatment sequencing

Resistance Monitoring

What it is: Testing for genetic changes that cause treatment resistance

How it's used:

• Monitoring during treatment
• Testing at progression
• Guiding next treatment choice

Examples:

• EGFR T790M mutation confers resistance to first-line EGFR inhibitors
• Newer drugs target resistance mutations
• Liquid biopsy particularly useful for monitoring

When Molecular Testing is Done

Initial diagnosis:

• To guide initial treatment selection
• Standard for many cancer types
• Often done on diagnostic biopsy tissue

At progression:

• To identify resistance mechanisms
• To guide subsequent treatment
• May use tissue or liquid biopsy

For clinical trials:

• To determine eligibility
• Some trials require specific mutations
• Can provide access to new therapies

Getting Your Test Results

Turnaround time:

• Single gene tests: 1-2 weeks
• Gene panels: 2-3 weeks
• Comprehensive NGS: 2-4 weeks
• Liquid biopsy: 1-2 weeks

Results report includes:

• Mutations found
• Interpretation of significance
• Potential treatment implications
• Clinical trial suggestions (sometimes)

Discussing results:

• Results should be discussed with your oncologist
• May involve molecular tumor board review
• Genetic counseling may be recommended for germline mutations
• Results may change treatment recommendations

Technical Limitations

Sample quality:

• Need adequate tissue/cells
• Poor sample may yield insufficient results
• Sometimes new biopsy is needed

Detection limits:

• Some mutations may be present at very low levels
• Current tests may miss very low frequency mutations
• Heterogeneity can lead to sampling error

Interpretation challenges:

• Variants of uncertain significance (VUS)
• Not all mutations are well understood
• Different mutations have different implications

Clinical Limitations

Not all mutations have targeted treatments:

• Many mutations are not yet "actionable"
• Some mutations have no clear treatment implication
• Research is ongoing to find new treatments

Insurance coverage:

• Not all tests are covered
• Coverage varies by insurer and indication
• Prior authorization often required

Access and availability:

• Not available at all hospitals
• May need to send to specialized labs
• Results may take longer if sent out

Tissue-Agnostic Therapy

Revolutionary concept:

• Treat based on genetic alteration, not tumor location
• First FDA-approved tissue-agnostic therapies for NTRK fusions and MSI-H
• Expanding to other alterations

Examples:

• NTRK inhibitors for any NTRK-fusion positive cancer
• Pembrolizumab for any MSI-H/dMMR solid tumor
• RET inhibitors for RET-altered tumors

Comprehensive Molecular Profiling

Standard of care evolution:

• Moving toward testing all genes at once
• More efficient than sequential single-gene tests
• Provides complete picture upfront
• Guides treatment sequence

Early Detection

Future application:

• Using molecular testing to detect cancer earlier
• Liquid biopsy for screening
• Detecting cancer before symptoms appear
• Currently under active investigation

Who Should Have Molecular Testing?

Standard for:

• Advanced lung adenocarcinoma
• Metastatic breast cancer
• Metastatic colorectal cancer
• Melanoma
• Many other advanced cancers

Consider for:

• Rare or unusual cancers
• Cancers not responding to standard treatment
• When considering clinical trials
• When tissue is adequate

Cost and Insurance

Typical costs:

• Single gene tests: $200-$600
• Gene panels: $1,000-$5,000
• Comprehensive NGS: $3,000-$7,000

Insurance coverage:

• Often covered for advanced cancers
• Coverage varies by test and indication
• Prior authorization frequently required
• Financial assistance may be available

Genetic Counseling

When recommended:

• If germline (inherited) mutations found
• Strong family history of cancer
• Young age at diagnosis
• Considering testing for hereditary cancer syndromes

What genetic counselors do:

• Explain inheritance patterns
• Discuss testing implications for family
• Help with decision-making
• Provide psychological support

Before molecular testing:

1. What molecular tests do you recommend for my cancer?
2. What information do you hope to get from testing?
3. How will results change my treatment options?
4. Will insurance cover this testing?
5. What if we don't find any actionable mutations?
6. Do I need genetic counseling?

After receiving results:

1. What mutations did you find?
2. What do these mutations mean for my treatment?
3. Are there targeted therapies for my mutations?
4. Are there clinical trials I should consider?
5. Should my family members be tested?

Is molecular testing the same as genetic testing for inherited cancer risk?

”

No. Molecular pathology usually tests for somatic mutations - genetic changes in the cancer cells that developed during your lifetime and aren't inherited. Genetic testing for inherited cancer risk looks for germline mutations - changes you were born with that can be passed to your children. Some molecular tests may incidentally find germline mutations, which would then require genetic counseling.

What if my molecular testing finds no actionable mutations?

”

This is common and doesn't mean you're out of options. Many cancers don't have currently targetable mutations. Standard chemotherapy, immunotherapy, radiation, and surgery remain effective treatments. Additionally, new targeted therapies are constantly being developed, and your cancer may have a target in the future. Clinical trials may also be an option.

Can molecular testing be done on old biopsy samples?

”

Sometimes, but it depends. Molecular testing requires adequate tissue with preserved DNA/RNA. Older samples may be degraded or insufficient. If you had a biopsy in the past, it may be possible to use that tissue if it was properly stored and enough remains. Otherwise, a new biopsy may be needed.

How often should molecular testing be repeated?

”

It depends on the clinical situation. Molecular testing is typically done at initial diagnosis to guide treatment. It may be repeated if the cancer progresses or stops responding to treatment, as new mutations can develop. Liquid biopsy testing can be done more frequently to monitor for resistance mutations. Your doctor will recommend the appropriate timing based on your situation.

Will my insurance cover molecular testing?

”

Many insurance plans cover molecular testing for advanced cancers, but coverage varies. Testing is more likely to be covered when it's considered standard of care for your cancer type and stage. Coverage may be less certain for experimental tests or panels that include many genes. Check with your insurance company and ask your doctor's office to help with prior authorization.

What if my test shows a "variant of uncertain significance"?

”

A VUS is a genetic change whose significance is not yet known. As research advances, some VUS will be reclassified as benign (harmless) or pathogenic (disease-causing). Currently, a VUS should not be used to make treatment decisions. Your doctor may recommend monitoring as more information becomes available, or additional testing.

Can molecular testing predict if my cancer will respond to treatment?

”

Molecular testing can predict response to certain targeted therapies. For example, EGFR mutations predict response to EGFR inhibitors in lung cancer. However, molecular testing cannot predict response to all treatments, and even when a target is present, response is not guaranteed. Other factors also influence treatment effectiveness.

Should I seek a second opinion of my molecular test results?

”

Molecular test results are often reviewed by molecular tumor boards, which include multiple specialists who interpret complex results. If you're unsure about the results or their implications, seeking a second opinion - particularly at a center with expertise in molecular oncology - can be valuable. This is especially true for rare mutations or when standard treatment options have been exhausted.

Molecular pathology has revolutionized cancer care by enabling personalized treatment based on the unique genetic characteristics of each person's cancer. By understanding the molecular drivers of cancer, doctors can select targeted therapies that are more effective and often less toxic than traditional chemotherapy.

While not all cancers have currently targetable mutations, the field is rapidly evolving. New targets and treatments are constantly being discovered, and molecular testing is becoming standard for many cancer types. Your molecular profile provides crucial information that guides your treatment journey.

If molecular testing is recommended for your cancer, discuss the benefits, limitations, and implications with your healthcare team. Understanding your results empowers you to participate in treatment decisions and access the most appropriate therapies for your specific cancer.

Learn more:

• American Association for Cancer Research: aacr.org
• American Society of Clinical Oncology: asco.org
• College of American Pathologists: cap.org
• National Cancer Institute: cancer.gov
• Personalized Medicine Coalition: personalizedmedicinecoalition.org

Find support:

• American Cancer Society Helpline: 1-800-227-2345
• Cancer Support Community: cancersupportcommunity.org
• FORCE: Facing Hereditary Cancer Empowered: facingourrisk.org

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations.

Sources:

• American Association for Cancer Research. "Molecular Profiling in Cancer." 2024.
• American Society of Clinical Oncology. "Molecular Testing for Cancer." 2024.
• College of American Pathologists. "Molecular Pathology Guidelines." 2024.
• National Cancer Institute. "Targeted Cancer Therapies." 2024.
• Journal of Clinical Oncology. "Implementation of Molecular Testing." 2024.
• National Cancer Institute. "Targeted Cancer Therapies." 2024.